Literature DB >> 23132337

Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection.

Julia Lüke1, Khaled Nassar, Salvatore Grisanti, Matthias Lüke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23132337     DOI： 10.1007/s00417-012-2184-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  14 in total

Review 1.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Authors:  Napoleone Ferrara; Kenneth J Hillan; Hans-Peter Gerber; William Novotny
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration.

Authors:  Hamid Hosseini; Mehrzad Lotfi; Mina Heidari Esfahani; Nariman Nassiri; Mohammad Reza Khalili; Mohammad Reza Razeghinejad; Kouros Nouri-Mahdavi
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

3.  Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration.

Authors:  Maria-Andreea Gamulescu; Horst Helbig
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

4.  Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

Authors:  Robert L Avery
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

5.  Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.

Authors:  Kayako Matsuyama; Nahoko Ogata; Masato Matsuoka; Mitsumasa Wada; Tetsuya Nishimura; Kanji Takahashi
Journal:  J Ocul Pharmacol Ther       Date:  2011-08       Impact factor: 2.671

6.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Authors:  Paul Mitchell; Francesco Bandello; Ursula Schmidt-Erfurth; Gabriele E Lang; Pascale Massin; Reinier O Schlingemann; Florian Sutter; Christian Simader; Gabriela Burian; Ortrud Gerstner; Andreas Weichselberger
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

Review 7.  Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.

Authors:  C H Meyer; F G Holz
Journal:  Eye (Lond)       Date:  2011-04-01       Impact factor: 3.775

8.  Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Authors:  Taizo Yamazaki; Hideki Koizumi; Tetsuya Yamagishi; Shigeru Kinoshita
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

9.  Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.

Authors:  Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf
Journal:  Diabetes Care       Date:  2010-11       Impact factor: 19.112

10.  Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids.

Authors:  M Ehrenberg; B W McCuen; R H Schindler; R Machemer
Journal:  Ophthalmology       Date:  1984-04       Impact factor: 12.079
View more
  1 in total

1.  Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.

Authors:  Katarzyna Michalska-Małecka; Adam Kabiesz; Malgorzata W Kimsa; Barbara Strzałka-Mrozik; Maria Formińska-Kapuścik; Malgorzata Nita; Urszula Mazurek
Journal:  Clin Interv Aging       Date:  2016-03-24       Impact factor: 4.458
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.